ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025

Full Phase 3 results in people with type 2 diabetes in China with THDB0206 (BioChaperone® Lispro) presented at the American Diabetes Association (ADA) 86th Scientific Session

Positive topline results, released in July 2025, included non inferior HbA1c reduction for the whole population and a similar safety profile compared to the standard of care, Humalog®

Clinically relevant benefits over Humalog® include:

Superior long term glycemic control in people using Metformin or with HbA1c below 8.5%